Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00410982 · ClinicalTrials.gov registry record · Phase 1
Gemcitabine Plus Busulfan, Melphalan and Hematopoietic Cell Transplant for Advanced Lymphoid Malignancies
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 145
- Enrollment target
NCT00410982: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT00410982 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 145 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00410982, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 145 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to find the highest tolerated dose of gemcitabine that can be given with busulfan and melphalan. The safety of this drug combination will also be studied.
Interventions
- DRUG Melphalan
- DRUG Busulfan
- DRUG Gemcitabine
- OTHER Hematopoietic Cell Transplantation
- DRUG Rituximab for Patients with B-Cell Malignancies
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 145 participants |
| Start Date | 2006-12 |
| Est. Completion | 2012-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00410982
The ClinicalTrials.gov registry entry for NCT00410982 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 145 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Melphalan is the first listed.
NCT00410982 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00410982 about?
NCT00410982 is a clinical study titled "Gemcitabine Plus Busulfan, Melphalan and Hematopoietic Cell Transplant for Advanced Lymphoid Malignancies". The goal of this clinical research study is to find the highest tolerated dose of gemcitabine that can be given with busulfan and melphalan. The safety of this drug combination will also be studied.
What is the current status of trial NCT00410982?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 145 participants. The study started on 2006-12. Estimated completion is 2012-09.
What interventions are being tested in trial NCT00410982?
The interventions under investigation include: Melphalan (DRUG), Busulfan (DRUG), Gemcitabine (DRUG), Hematopoietic Cell Transplantation (OTHER), Rituximab for Patients with B-Cell Malignancies (DRUG).
Who is sponsoring clinical trial NCT00410982?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.